# Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

> **NCT00383760** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Pancreatic Cancer
- Recurrent Pancreatic Cancer
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** eribulin mesylate

## Key facts

- **NCT ID:** NCT00383760
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383760, "Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00383760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*